These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 29697768)

  • 1. A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.
    Edwards JE; Schwartz MM; Schmidt CS; Sobel JD; Nyirjesy P; Schodel F; Marchus E; Lizakowski M; DeMontigny EA; Hoeg J; Holmberg T; Cooke MT; Hoover K; Edwards L; Jacobs M; Sussman S; Augenbraun M; Drusano M; Yeaman MR; Ibrahim AS; Filler SG; Hennessey JP
    Clin Infect Dis; 2018 Jun; 66(12):1928-1936. PubMed ID: 29697768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
    Ibrahim AS; Luo G; Gebremariam T; Lee H; Schmidt CS; Hennessey JP; French SW; Yeaman MR; Filler SG; Edwards JE
    Vaccine; 2013 Nov; 31(47):5549-56. PubMed ID: 24063977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice.
    Alqarihi A; Singh S; Edwards JE; Ibrahim AS; Uppuluri P
    Sci Rep; 2019 Apr; 9(1):6194. PubMed ID: 30996274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.
    Uppuluri P; Singh S; Alqarihi A; Schmidt CS; Hennessey JP; Yeaman MR; Filler SG; Edwards JE; Ibrahim AS
    Front Immunol; 2018; 9():1349. PubMed ID: 29963049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects.
    Cassone A
    BJOG; 2015 May; 122(6):785-794. PubMed ID: 25052208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection.
    Singh S; Uppuluri P; Mamouei Z; Alqarihi A; Elhassan H; French S; Lockhart SR; Chiller T; Edwards JE; Ibrahim AS
    PLoS Pathog; 2019 Aug; 15(8):e1007460. PubMed ID: 31381597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.
    Schmidt CS; White CJ; Ibrahim AS; Filler SG; Fu Y; Yeaman MR; Edwards JE; Hennessey JP
    Vaccine; 2012 Dec; 30(52):7594-600. PubMed ID: 23099329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis.
    Ge G; Yang Z; Li D; Zhang N; Chen B; Shi D
    Front Immunol; 2022; 13():959740. PubMed ID: 35967437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis.
    Brand SR; Degenhardt TP; Person K; Sobel JD; Nyirjesy P; Schotzinger RJ; Tavakkol A
    Am J Obstet Gynecol; 2018 Jun; 218(6):624.e1-624.e9. PubMed ID: 29534874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.
    Sobel JD; Donders G; Degenhardt T; Person K; Curelop S; Ghannoum M; Brand SR
    NEJM Evid; 2022 Aug; 1(8):EVIDoa2100055. PubMed ID: 38319878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees.
    Millar EV; Bennett JW; Barin B; Carey PM; Law NN; English CE; Schwartz MM; Cochrane T; Ellis MW; Tribble DR; Timothy Cooke M; Hennessey JP
    Vaccine; 2021 May; 39(23):3179-3188. PubMed ID: 33962841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent vulvovaginal candidiasis.
    Sobel JD
    Am J Obstet Gynecol; 2016 Jan; 214(1):15-21. PubMed ID: 26164695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.
    Fan S; Liu X; Wu C; Xu L; Li J
    Mycopathologia; 2015 Feb; 179(1-2):95-101. PubMed ID: 25416649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis.
    Zhu YX; Li T; Fan SR; Liu XP; Liang YH; Liu P
    Health Qual Life Outcomes; 2016 Apr; 14():65. PubMed ID: 27129474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida albicans allergen immunotherapy in recurrent vaginal candidiasis.
    Moraes PS; de Lima Goiaba S; Taketomi EA
    J Investig Allergol Clin Immunol; 2000; 10(5):305-9. PubMed ID: 11108444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic enzyme therapy in the treatment of recurrent vulvovaginal candidiasis].
    Unzeitig V; Dvořák V; Hlaváčková O; Malík T; Nový J; Stará A; Skřivánek A; Stěpán J
    Ceska Gynekol; 2013 Apr; 78(2):187-94. PubMed ID: 23710984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial.
    Witt A; Kaufmann U; Bitschnau M; Tempfer C; Ozbal A; Haytouglu E; Gregor H; Kiss H
    BJOG; 2009 Oct; 116(11):1499-505. PubMed ID: 19583713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review.
    Lanier C; Melton TC
    Ann Pharmacother; 2024 Jun; 58(6):636-644. PubMed ID: 37650387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbicidal activity of neutrophils is inhibited by isolates from recurrent vaginal candidiasis (RVVC) caused by Candida albicans through fungal thioredoxin reductase.
    Ratti BA; Godoy JS; de Souza Bonfim Mendonça P; Bidóia DL; Nakamura TU; Nakamura CV; Lopes Consolaro ME; Estivalet Svidzinski TI; de Oliveira Silva S
    Cell Immunol; 2015 Jan; 293(1):22-9. PubMed ID: 25497972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.
    Schuman P; Capps L; Peng G; Vazquez J; el-Sadr W; Goldman AI; Alston B; Besch CL; Vaughn A; Thompson MA; Cobb MN; Kerkering T; Sobel JD
    Ann Intern Med; 1997 May; 126(9):689-96. PubMed ID: 9139554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.